
|Videos|June 16, 2017
The Complexity of the PARP Inhibitor Landscape in Ovarian Cancer
Author(s)Douglas A. Levine, MD
Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Divison of Gynecologic Oncology, NYU Langone Medical Center, discusses the impact of PARP inhibitors on the landscape of ovarian cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
2
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
3
Off-the-Shelf In Vivo BCMA CAR T KLN-1010 Yields Deep R/R Myeloma Responses
4
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
5










































